142 related articles for article (PubMed ID: 11776372)
1. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses.
Whitmore MM; Li S; Falo L; Huang L
Cancer Immunol Immunother; 2001 Dec; 50(10):503-14. PubMed ID: 11776372
[TBL] [Abstract][Full Text] [Related]
2. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth.
Whitmore M; Li S; Huang L
Gene Ther; 1999 Nov; 6(11):1867-75. PubMed ID: 10602382
[TBL] [Abstract][Full Text] [Related]
3. The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo.
Tan Y; Li S; Pitt BR; Huang L
Hum Gene Ther; 1999 Sep; 10(13):2153-61. PubMed ID: 10498247
[TBL] [Abstract][Full Text] [Related]
4. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
[TBL] [Abstract][Full Text] [Related]
5. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
6. Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG-independent, direct cytotoxic effects in cell cultures and in mice.
Khazanov E; Simberg D; Barenholz Y
J Gene Med; 2006 Aug; 8(8):998-1007. PubMed ID: 16741997
[TBL] [Abstract][Full Text] [Related]
7. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex.
Kuramoto Y; Nishikawa M; Hyoudou K; Yamashita F; Hashida M
J Control Release; 2006 Oct; 115(2):226-33. PubMed ID: 16996162
[TBL] [Abstract][Full Text] [Related]
9. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
Roda JM; Parihar R; Carson WE
J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
[TBL] [Abstract][Full Text] [Related]
10. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.
Wang D; Li Y; Yu D; Song SS; Kandimalla ER; Agrawal S
Int J Oncol; 2004 Apr; 24(4):901-8. PubMed ID: 15010828
[TBL] [Abstract][Full Text] [Related]
11. Efficient peritoneal dissemination treatment obtained by an immunostimulatory phosphorothioate-type CpG DNA/cationic liposome complex in mice.
Kuramoto Y; Kawakami S; Zhou S; Fukuda K; Yamashita F; Hashida M
J Control Release; 2008 Mar; 126(3):274-80. PubMed ID: 18237815
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the type of liposome involving cytokine production induced by non-CpG Lipoplex in macrophages.
Yasuda S; Yoshida H; Nishikawa M; Takakura Y
Mol Pharm; 2010 Apr; 7(2):533-42. PubMed ID: 20047296
[TBL] [Abstract][Full Text] [Related]
13. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN.
Mansourian M; Badiee A; Jalali SA; Shariat S; Yazdani M; Amin M; Jaafari MR
Immunol Lett; 2014 Nov; 162(1 Pt A):87-93. PubMed ID: 25086399
[TBL] [Abstract][Full Text] [Related]
14. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
Weeratna RD; Brazolot Millan CL; McCluskie MJ; Davis HL
FEMS Immunol Med Microbiol; 2001 Dec; 32(1):65-71. PubMed ID: 11750224
[TBL] [Abstract][Full Text] [Related]
15. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.
Mui B; Raney SG; Semple SC; Hope MJ
J Pharmacol Exp Ther; 2001 Sep; 298(3):1185-92. PubMed ID: 11504819
[TBL] [Abstract][Full Text] [Related]
16. Liposome-encapsulated CpG enhances antitumor activity accompanying the changing of lymphocyte populations in tumor via intratumoral administration.
Kim DH; Moon C; Oh SS; Park S; Jeong JW; Kim S; Lee HG; Kwon HJ; Kim KD
Nucleic Acid Ther; 2015 Apr; 25(2):95-102. PubMed ID: 25692533
[TBL] [Abstract][Full Text] [Related]
17. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model.
Heckelsmiller K; Rall K; Beck S; Schlamp A; Seiderer J; Jahrsdörfer B; Krug A; Rothenfusser S; Endres S; Hartmann G
J Immunol; 2002 Oct; 169(7):3892-9. PubMed ID: 12244187
[TBL] [Abstract][Full Text] [Related]
18. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
19. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
20. G-quadruplex-based CpG oligodeoxynucleotide/DOTAP complex strongly stimulates immunity in CpG motif-specific and loop-length-dependent manners.
Tu ATT; Hoshi K; Shobo M; Yamazaki T
Nanomedicine; 2022 Feb; 40():102508. PubMed ID: 34906721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
